Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews

Sao Paulo Medical Journal - Tập 128 Số 3 - Trang 141-166 - 2010
Tamara Melnik1, Bernardo Garcia de Oliveira Soares1, Maria Eduarda dos Santos Puga1, Álvaro Nagib Atallah1
1Universidade Federal de São Paulo, Brazil

Tóm tắt

CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS) is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. METHODS: This was a critical appraisal of Cochrane reviews published in the Cochrane Library, supplemented with reference to more recent randomized controlled trials (RCTs) on RS. The following databases were searched: Medical Literature Analysis and Retrieval System Online (Medline) (1966-2009), Controlled Trials of the Cochrane Collaboration (2009, Issue 2), Embase (Excerpta Medica) (1980-2009), Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs) (1982-2009). There was no language restriction. Randomized controlled trials, systematic reviews and meta-analyses evaluating atypical antipsychotics for treating RS were included. RESULTS: Seven Cochrane systematic reviews and 10 additional RCTs were included in this review. The data generally showed minor differences between the atypical antipsychotics evaluated and typical antipsychotics, regarding improvement in disease symptoms, despite better adherence to treatment with atypical antipsychotics. Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine. CONCLUSIONS: The findings underscore the difficulty in treating these patients, with high dropout rates and treatment patterns of modest improvement in assessments of effectiveness. Atypical antipsychotics have advantages over typical antipsychotics mainly through their better safety profile, which leads to better adherence to treatment. A combination of antipsychotics may also be an option for some refractory patients.

Từ khóa


Tài liệu tham khảo

Wiersma D, 1998, Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort, Schizophr Bull, 24, 75, 10.1093/oxfordjournals.schbul.a033315

Barnes TRE, 2003, Treatment-resistant schizophrenia, 2, 489

Altamura AC, 2005, Some biological correlates of drug resistance in schizophrenia: a multidimensional approach, World J Biol Psychiatry, 6, 23, 10.1080/15622970510030027

Meltzer HY, 1997, Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance, Am J Psychiatry, 154, 475, 10.1176/ajp.154.4.475

Henna J, 1999, Predictors of response and outcome in treatment resistant versus non treatment resistant schizophrenic patients, Schizophrenia Research, 36, 281

2002

Brenner HD, 1990, Defining treatment refractoriness in schizophrenia, Schizophr Bull, 16, 551, 10.1093/schbul/16.4.551

Kane J, 1988, Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine, Arch Gen Psychiatry, 45, 789, 10.1001/archpsyc.1988.01800330013001

El-Sayeh HG, 2006, Aripiprazole for schizophrenia, Cochrane Database Syst Rev, CD004578

Bhattacharjee J, 2008, Aripiprazole versus typical antipsychotic drugs for schizophrenia, Cochrane Database Syst Rev, CD006617

Nussbaum AM, 2008, Paliperidone for schizophrenia, Cochrane Database Syst Rev, CD006369

Srisurapanont M, 2004, Quetiapine for schizophrenia, Cochrane Database Syst Rev, CD000967

Hunter RH, 2003, Risperidone versus typical antipsychotic medication for schizophrenia, Cochrane Database Syst Rev, CD000440

Gilbody SM, 2000, Risperidone versus other atypical antipsychotic medication for schizophrenia, Cochrane Database Syst Rev, CD002306

Jayaram MB, 2006, Risperidone versus olanzapine for schizophrenia, Cochrane Database Syst Rev, CD005237

Moher D, 2008, When and how to update systematic reviews, Cochrane Database Syst Rev, MR000023

Carson WH, 2002

Kane J, 2003

Daniel DG, 2004

Oren D, 2005

Carson WH, 2000

Carson WH, 2000, Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo, European Neuropsychopharmacology, 10, S309, 10.1016/S0924-977X(00)80358-2

Csernansky JG, 2003, Treatment of schizophrenia: preventing the progression of disease, Psychiatr Clin North Am, 26, 367, 10.1016/S0193-953X(02)00113-2

Daniel DG, 2000, Aripiprazole, a novel antipsychotic: overview of a phase II study result, International Journal of Neuropsychopharmacology, 3

Kujawa M, 2002, Aripiprazole for long-term maintenance treatment of schizophrenia, International Journal of Neuropsychopharmacology, 5

Chang JS, 2008, Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial, J Clin Psychiatry, 69, 720, 10.4088/JCP.v69n0505

Kane JM, 2007, Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine, J Clin Psychiatry, 68, 213, 10.4088/JCP.v68n0206

Davidson M, 2007, Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study, Schizophr Res, 93, 117, 10.1016/j.schres.2007.03.003

Kramer M, 2007, Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study, J Clin Psychopharmacol, 27, 6, 10.1097/JCP.0b013e31802dda4a

Marder SR, 2007, Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study, Biol Psychiatry, 62, 1363, 10.1016/j.biopsych.2007.01.017

Tzimos A, 2006

Turkoz I, 2008, Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia, Neuropsychiatr Dis Treat, 4, 949

Canuso CM, 2009, Randomized, double-blind, placebo-controlled study of paliperidone extended-release quetiapine in inpatients with recently exacerbated schizophrenia, Am J Psychiatry, 166, 691, 10.1176/appi.ajp.2009.08040613

Hirsch S, 1994, A multicentre, double-blind, placebo-controlled comparison of low and high dosage regimens of SeroquelTM in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia, European Neuropsychopharmacology, 4, 384, 10.1016/0924-977X(94)90211-9

Link CGG, 1995, 'Seroquel' treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia: A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimens, European Neuropsychopharmacology, 5, 346

Small JG, 1997, Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Seroquel Study Group, Arch Gen Psychiatry, 54, 549, 10.1001/archpsyc.1997.01830180067009

Addington DE, 1996

Arvanitis LA, 1996, 'Seroquel' (ICI 204,636): an atypical antipsychotic: results from a multiple fixed dose, placebo-controlled study, European Neuropsychopharmacology, 6, 10.1016/0924-977X(96)87987-9

Arvanitis LA, 1996

Arvanitis LA, 1997

Arvanitis LA, 1997, Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group, Biol Psychiatry, 42, 233, 10.1016/S0006-3223(97)00190-X

Arvanitis LA, 1966, ICI 204,636, an atypical antipsychotic: results from a multiple fixed-dose, placebo-controlled trial, Psychopharmacology Bulletin, 32

Borison RL, 1996, A comparison of five fixed doses of 'seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia, Schizophrenia Research, 18, 10.1016/0920-9964(96)85441-7

Borison RL, 1996, A multiple fixed-dose, placebo-controlled trial with 'seroquel': An atypical antipsychotic, Biological Psychiatry, 39, 597, 10.1016/0006-3223(96)84278-8

Cantillon M, 1998

Cantillon M, 1998

Cantillon M, 1998

Hong WW, 1996, 'Seroquel' (ICI 204,636): not different from placebo for EPS or prolactin, Biological Psychiatry, 39

Hong WW, 1996, 'Seroquel' (ICI 204-636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin, European Neuropsychopharmacology, 6

Hong WW, 1996

Hong WW, 1995

Fabre LF, 1995, ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia, Clin Ther, 17, 366, 10.1016/0149-2918(95)80102-2

Borison RL, 1996, ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia, J Clin Psychopharmacol, 16, 158, 10.1097/00004714-199604000-00008

Arvanitis L, 1994, A multicentre, placebo-controlled double-blind evaluation of SeroquelTM in hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia, European Neuropsychopharmacology, 4, 10.1016/0924-977X(94)90213-5

Link CGG, 1995, SeroquelTM treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia: A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimens, European Neuropsychopharmacology, 5, 346

Barzega G, 1999, Efficacia e tollerabilita dell' antipsychotico atipico quetiapina: uno studio in doppio cieco, Minerva Psichiatrica, 40, 297

Barzega G, 2000, Quetiapine in schizophrenic patients: a high- and low-dose double-blind comparison, European Journal of Psychiatry, 14, 221

Fleischhacker WW, 1995

King DJ, 1996, 'Seroquel' (ICI 204636): an atypical antipsychotic - results from Phase III, European Neuropsychopharmacology, 6

King DJ, 1996

King DJ, 1998, A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia, Psychopharmacology (Berl), 137, 139, 10.1007/s002130050603

Reuther E, 1996, Results of a multicenter study comparing the dosage and the dosage regimen of ICI 204,636 ('Seroquel'), Nervenarzt, 67

Purdon SE, 2000, Long-term treatment of quetiapine improves cognitive function in schizophrenia, Biological Psychiatry, 47, 10.1016/S0006-3223(00)00402-9

Purdon SE, 2001, Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol, J Psychiatry Neurosci, 26, 137

Copolov DL, 2000, A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia, Psychol Med, 30, 95, 10.1017/S0033291799001476

Fleishhacker W, 1996, ICI 204,636 (Seroquel): a putative new antipsychotic: results from Phase III trials, Schizophrenia Research, 18

Hellewell JSE, 1996, Switching from a conventional antipsychotic (haloperidol) to an atypical antipsychotic ('Seroquel'-ICI 204,636), European Neuropsychopharmacology, 6

Link C, 1996

Empfield JR

Link C, 1994, A multicentre, double-blind, controlled comparison of SeroquelTM and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia, European Neuropsychopharmacology, 4, 10.1016/0924-977X(94)90212-7

Peuskens J, 1997, A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia, Acta Psychiatr Scand, 96, 265, 10.1111/j.1600-0447.1997.tb10162.x

Buckley PF, 2001

Emsley RA, 1999

Emsley RA, 2001, Treatment of depressive symptoms in partially refractory schizophrenia: efficacy of quetiapine versus haloperidol, European Neuropsychopharmacology, 11, 10.1016/S0924-977X(01)80319-9

Emsley RA, 1999, Efficacy and tolerability of 'Seroquel' compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment, European Neuropsychopharmacology, 9, 10.1016/S0924-977X(99)80283-1

Emsley RA, 2000, A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment: PRIZE Study Group, Int Clin Psychopharmacol, 15, 121, 10.1097/00004850-200015030-00001

Emsley RA, 2000, Efficacy of seroquel in treating all of the positive and negative symptoms of schizophrenia, Schizofrenia Research, 41

Goldstein JM, 2000

Nasrallah HA, 2001, Patterns of response in patients with schizophrenia partially responsive to fluphenazine and switched to quetiapine or haloperidol, European Neuropsychopharmacology, 11, 10.1016/S0924-977X(01)80314-X

Weiden PJ, 2001, Switching from fluphenazine to quetiapine ameliorates extrapyramidal symptoms and neuroendocrine side effects in patients with schizophrenia, European Neuropsychopharmacology, 11, S262, 10.1016/S0924-977X(01)80315-1

Kudo Y, 2000, Clinical evaluation of quetiapine fumarate for the treatment of schizophrenia: a double-blind controlled study using mosapramine hydrochloride as a control, Rinsyo Iyaku, 16, 1807

Kudo Y, 1999

Mullen J, 2001, A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study, Clin Ther., 23, 1839, 10.1016/S0149-2918(00)89080-3

Tandon R, 2001

Conley RR, 2005, Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia, Clin Neuropharmacol, 28, 163, 10.1097/01.wnf.0000172993.89879.0f

Genç Y, 2007, Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study, Adv Ther, 24, 1, 10.1007/BF02849987

Blin O, 1996, Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients, J Clin Psychopharmacol, 16, 38, 10.1097/00004714-199602000-00007

Chouinard G, 1993, A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients, J Clin Psychopharmacol, 13, 25, 10.1097/00004714-199302000-00004

Claus A, 1992, Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparitive study, Acta Psychiatr Scand, 85, 295, 10.1111/j.1600-0447.1992.tb01473.x

Hoyberg OJ, 1993, Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations, Acta Psychiatr Scand, 88, 395, 10.1111/j.1600-0447.1993.tb03480.x

Huttunen MO, 1995, Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial, Acta Psychiatr Scand, 91, 271, 10.1111/j.1600-0447.1995.tb09781.x

Marder SR, 1994, Risperidone in the treatment of schizophrenia, Am J Psychiatry, 151, 825, 10.1176/ajp.151.6.825

Min SK, 1993, Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial, Yonsei Med J, 34, 179, 10.3349/ymj.1993.34.2.179

Peuskens J, 1995, Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group, Br J Psychiatry, 166, 712, 10.1192/bjp.166.6.712

Potkin SG, 1997

Bouchard RH, 1998

Mahmoud RA, 1998

Namjoshi M, 2002

Namjoshi M, 2002, Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial, Eur Neuropsychopharmacol, 10.1016/S0924-977X(02)80471-0

Conley RR, 2001, A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder, Am J Psychiatry, 158, 765, 10.1176/appi.ajp.158.5.765

Jeste DV, 2003, International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia, Am J Geriatr Psychiatry, 11, 638, 10.1097/00019442-200311000-00008

Tran PV, 1997, Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders, J Clin Psychopharmacol, 17, 407, 10.1097/00004714-199710000-00010

Lieberman JA, 2005, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N Engl J Med, 353, 1209, 10.1056/NEJMoa051688

Keefe RS, 2006, One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia, Schizophr Res, 81, 1, 10.1016/j.schres.2005.07.038

Purdon SE, 2000, Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol: The Canadian Collaborative Group for research in schizophrenia, Arch Gen Psychiatry, 57, 249, 10.1001/archpsyc.57.3.249

Casey DE, 2003, Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia, Neuropsychopharmacology, 28, 182, 10.1038/sj.npp.1300023

Hosalli P, 2003, Depot risperidone for schizophrenia, Cochrane Database Syst Rev, CD004161

Kane JM, 2003, Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic, Am J Psychiatry, 160, 1125, 10.1176/appi.ajp.160.6.1125

Suzuki T, 2008, Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone, Hum Psychopharmacol, 23, 455, 10.1002/hup.959

Freudenreich O, 2007, Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial, Schizophr Res, 92, 90, 10.1016/j.schres.2006.12.030

Lewis SW, 2006, Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia, Schizophr Bull, 32, 715, 10.1093/schbul/sbj067

Honer WG, 2006, Clozapine alone versus clozapine and risperidone with refractory schizophrenia, N Engl J Med, 354, 472, 10.1056/NEJMoa053222

Leucht S, 2009, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia, Am J Psychiatry, 166, 152, 10.1176/appi.ajp.2008.08030368

Rosa MA, 2005, Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia, Rev Bras Psiquiatr, 27, 178, 10.1590/S1516-44462005000300005

Kahn RS, 2008, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial, Lancet, 371, 1085, 10.1016/S0140-6736(08)60486-9

Correll CU, 2009, Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials, Schizophr Bull, 35, 443, 10.1093/schbul/sbn018